At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 9 enrolled
Drug / intervention
Ketorolac 0.4% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
In Brief
A Phase 4 clinical trial evaluating Ketorolac 0.4% and Lubricating Eye Drop for Inflammation. Completed, enrolled 9 participants across 1 site.
Detailed Summary
A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionAug 2009
TodayJul 2026
First PostedNov 14, 2008
Enrollment StartNov 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.6 years ago
Interventions
Ketorolac 0.4%drug
One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
Lubricating Eye Dropdrug
One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation